Dossier assessment

Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A22-95
Last updated

Report documents

  1. Extract of dossier assessment

    Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 776 kB, EN, not accessible
  2. Dossier assessment

    Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 860 kB, DE, not accessible

Dossier assessment

Indication:

Adult patients who have at least 4 migraine days per month

Result of dossier assessment:
  • Untreated and pretreated patients for whom conventional migraine prophylaxis is an option: added benefit not proven
  • Patients who do not respond to any of the following drug treatments/drug classes, for whom they are unsuitable, or who do not tolerate them: metoprolol, propranolol, flunarizine, topiramate, amitriptyline, clostridium botulinum toxin type A: added benefit not proven

Project details

Project no.
A22-95
Commission
Commission awarded on 31.08.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Head and nerves
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form